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a b s t r a c t 
The failure of artemisinin combination therapy (ACT) in malaria patients returning from endemic regions 
may be driven by parasite resistance to this treatment. ACT is used globally as the first-line treatment 
for Plasmodium falciparum malaria. However, artemisinin-resistant strains of P. falciparum have emerged 
and spread across Southeast Asia, with the risk of reaching high malaria burden regions in Africa and 
elsewhere. Here, we report on two malaria imported cases from Africa with possible parasite resistance 
to the ACT artemether-lumefantrine (AL). 
Case presentation: Two middle-aged males returning from Angola and Mozambique developed 
malaria symptoms in Portugal, where they were diagnosed and received treatment with AL as hospi- 
tal inpatients. After apparent cure and discharge from hospital, these individuals returned to hospital 
showing signs of late clinical failure. Molecular analysis was performed across a number of drug resis- 
tance associated genes. No evidence of pfk13 -mediated artemisinin resistance was found. Both subjects 
had complete parasite clearance after treatment with non-ACT antimalarials. 
Conclusion: Our case-studies highlights the need for close monitoring of signs of unsatisfactory anti- 
malarial efficacy among AL treated patients and the possible implication of other genes or mutations in 
the parasite response to ACTs. 
© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 
This is an open access article under the CC BY-NC-ND license 
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Despite the success of artemisinin combination therapy (ACT) 
n reducing the global burden of malaria, the emergence and 
pread of resistance to artemisinin threatens its use. ACT is used 
orldwide as the first-line treatment against uncomplicated fal- 
iparum malaria. ACT resistance, characterized by delayed para- 
ite clearance after treatment, is widespread in Southeast Asia 
 Imwong et al, 2017 ), but as yet there is no irrefutable evi-
ence of an established presence in Africa ( https://www.who. 
nt/malaria/areas/drug _ resistance/updates/en/ ). Nonetheless reports ty for Infectious Diseases. This is an open access article under the CC BY-NC-ND 
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Table 1 
Genotyping data from the two P. falciparum isolates taken from the recrudescence malaria episodes. 
Patient(case 1) Patient(case 2) 
Sex male male 
Age (years) 52 56 
Country of origin a ) Angola Mozambique 
Recrudescence time b) 22 days 21 days 
Drug resistance associated 
genes 
Genetic variation 
chloroquine or mefloquine 
pfcrt CVMNK CVMNK 
pfmdr1 wt wt 
pfmdr2 wt wt 
sulphadoxine-pyrimethamine 
pfdhfr 51I, 59R, 108N 51I, 59R, 108N 
pfdhps 540E 540E 
artemisinin combination therapies 
pfk13 wt wt 
pfpmII wt wt 
pfpmIII wt wt 
pfcoronin wt wt 
pfap2 μ 199T wt 
pfubp-1 615H, 956N, 1710S, 
1914N, 1915K, 2238K, 
3121N 
174N, 615H, 906N, 1133S, 1531D, 
1660I, 1914N, 1915K, 2238K, 2818Y, 
3103N 
a) Country where patients were infected 
b) elapsed time since primary malaria episode; wt, wild-type, sequence identical to the reference Plas- 
modium falciparum clone 3D7 (MRA-102); pfcrt (chloroquine resistance transporter; PF3D7_07090 0 0.1); 
pfmdr1 ( multidrug resistance protein 1; PF3D7_05230 0 0.1); pfmdr2 (multidrug resistance protein 2; 
PF3D7_1447900.1); pfdhfr (bifunctional dihydrofolate reductase-thymidylate synthase; PF3D7_0417200); 
pfdhps (hydroxymethyl dihydropterin pyrophosphokinase-dihydropteroate synthase; pfk13 (kelch13; 
PF3D7_134370 0); pfpmII (plasmepsinII; PF3D7_14080 0 0); pfpmIII (plasmepsinIII PF3D7_140810 0); pf- 
coronin (coronin; PF3D7_1251200); pfap2 μ (adaptor protein complex-2 μ subunit; PF3D7_1218300); 































































f therapeutic failure have emerged, including from Angola 
 Van et al, 2014 ). Artemether-lumefantrine (AL) is the most 
idely used ACT in sub-Saharan Africa, with some recent re- 
orts of the emergence of decreasing efficacy, supported by pa- 
ients remaining positive for Plasmodium 3 days after treatment 
 Madamet et al, 2017 ; Uwimana et al, 2020 ). The underlying mech-
nisms are not understood. 
Single nucleotide polymorphisms (SNPs) in the parasite gene 
fk13 are becoming established as molecular markers of slow 
arasite clearance rates after ACT ( Imwong et al, 2017 ), but 
hey have been identified rarely in Africa ( Madamet et al, 2017 ; 
aylor et al, 2015 ; Sutherland et al, 2017 ). Hence the variable ACT 
fficacy may be independent of pfk13 polymorphism, with sug- 
ested links to multi-locus genotypes encompassing pfcrt, pfmdr1, 
fcoronin, pfap2 μ or pfubp1 genes ( Sutherland et al, 2017 ). Specifi- 
ally, haplotype NFD (N86, 184F, D1246) in pfmdr1 , the mutation 
160N/T in pfap2 μ and D1525E, E1528D and E1531D in pfubp-1 
ave been involved in the development of tolerance or resistance 
o AL ( Henrici et al, 2020 ; Adamu et al, 2020 ). Here we present a
rief case report and genotyping data of parasites ( Table 1 ) isolated 
rom the recurrence episode of two patients returning to Portugal 
rom Angola and Mozambique. 
Malaria is a Notifiable Disease in Portugal and AL is used for 
he treatment of imported cases of P. falciparum . All parasite geno- 
yping tests performed were formally requested by the physicians 
irectly responsible for patient care. Patient identifiers were re- 
oved by the physicians directly responsible for the patient. Both 
atients signed a written informed consent for the analysis of par- 
site genes, under the IHMT Ethics Committee Approval n °11.18 
nd CHLO Ethics Committee Approval RNEC:2017070 0 050. 
ase 1 
A 52-year-old male presented to Centro Hospitalar Universitário 
e São João Emergency Department (CHUSJ-ED), Porto, Portugal 152 n August 2019 with malaria-compatible symptoms after travel- 
ing from Luanda, Angola. He had a high-grade fever during the 
our days preceding admission and developed prostration on the 
ay of admission (Day 0;D0). Dysfunctions on D0: neurological 
prostration, disorientation), cardiovascular (hypotension with hy- 
erlactacidaemia of 3.43 mmol/L) and hepatic (hyperbilirubinemia 
f 3.34 mg/dL). A malaria rapid test (BinaxNOW®) and a blood 
mear showed 7% parasitaemia. The patient was transferred to the 
ntensive Care Unit (D0) and treated with intravenous artesunate 
200mg) at 0h, 12h, 24h, 48h and 72h (D3) followed by a course of 
L for 3 consecutive days (4 pills AL 20/120mg at 0h, 8h, 20h, 32h, 
4h and 56h). The patient was discharged on D9 of in-hospital 
reatment. He stayed in Portugal and did not return to Angola. 
leven days after discharge (D19) he developed high-grade fever 
39 °C), nausea, vomiting and general malaise. Two days afterward 
D21), he presented to CHUSJ-ED. The patient did not show any rel- 
vant organ dysfunction. Analysis of blood smear led to a positive 
esult for P. falciparum (confirmed by polymerase chain reaction; 
CR) with 8.5% parasitaemia. The patient was treated with intra- 
enous quinine (600mg) and doxycycline (200mg) for 7 days. Par- 
sitaemia became negative and the patient improved. The patient 
as followed in the outpatient clinic and remained asymptomatic 
ntil return to Angola (D28). 
ase 2 
A 56-year-old male presented to the emergency department of 
entro Hospitalar Lisboa Ocidental (CHLO), Lisbon, Portugal in July 
019 with symptoms compatible with malaria after returning from 
ozambique, Nacala, where he was residing since 2013. For the 
revious two days he had malaise, chills, profuse sweating, nau- 
ea and episodic vomiting. On admission (D0) to the CHLO infec- 
ious diseases ward, the patient presented: fever (38.5 °C), tachy- 
ardia without hypotension, jaundice, tender abdomen, thrombo- 
ytopenia (38 × 10 9 /L), hyperbilirubinemia (2,55 mg/dL), elevated 
























































































M  iver enzymes (AST 119 U/L, ALT 434 U/L, GGT 493 U/L) and high 
-reactive protein (23,9 mg/dL). The blood smear presented 6% P. 
alciparum parasitaemia with peripheral schizont clusters. He was 
reated (D0) with a full course of oral AL (20/120mg) for three con- 
ecutive days (four AL pills at 0h, 8h, 24h, 36h, 48h and 60h). On 
3 parasitaemia was negative, along with remission of symptoms. 
he patient was discharged five days after admission and referred 
o the outpatient clinic, presenting (D8) without symptoms or par- 
sitaemia. The patient stayed in Portugal and did not travel abroad. 
ymptoms recurred thirteen days later (D21) and the patient was 
eadmitted to the hospital (D23) without evidence of organ dys- 
unction. A blood smear revealed 3% P. falciparum parasitaemia and 
as confirmed by PCR. The patient was successfully treated with 
even days of intravenous quinine (10mg/Kg of body weight every 
ight hours) and doxycycline (200mg/day). The patient was asymp- 
omatic and had clearance of parasitaemia by the fourth day of 
reatment (D26). He was discharged from the hospital (D29) and 
resented without symptoms up until his last follow-up in the out- 
atient clinic (D35). 
iscussion 
P. falciparum drug resistance genes were sequenced and anal- 
sed in parasite isolates from the recurrence episode of both 
atients ( Table 1 ). In line with other findings from Africa 
 Madamet et al, 2017 ; Taylor et al, 2015 ; Sutherland et al, 2017 )
o SNPs in pfk13 were identified. Pfmdr1 and chloroquine-sensitive 
fcrt haplotype (CVMNK) were present in both parasite isolates, 
greeing with a significant decline in the frequency observed af- 
er withdrawal of chloroquine in Africa ( Ocan et al, 2019 ). Mozam- 
ique withdrew chloroquine in 2002 and Angola in 2004 and 
oth countries have been using ACTs (mostly AL) since 2006. 
he pfap2 μ polymorphism identified has not been previously as- 
ociated with delayed parasite clearance and only one of the 
reviously reported pfubp-1 polymorphisms (E1531D) ( Adams et 
, 2018 ; Henrici et al, 2020 ) was detected. Although the role 
layed by both genes in artemisinin action is not fully under- 
tood, the biological processes in which they are involved make 
hem strong candidates. Pfap2 μ is part of the complex multi- 
enic signature of artemisinin susceptibility in Southeast Asia 
 Cerqueira et al, 2017 ) and is essential for parasite survival inside 
he erythrocyte ( Henrici et al, 2020 ). Pfubp-1 encodes a deubiqui- 
inating enzyme part of the ubiquitin-proteasome system, which 
s crucial for protein recycling and stress response. An enhanced 
tress response, with lower levels of ubiquitination, delays cell 
eath and confers resistance to artemisinin ( Dogovski et al, 2015 ). 
reatment failure cannot be fully attributed to parasite resistance 
n these two patients since: a) no SNPs in the loci previously 
inked to reduced susceptibility to AL ( pfk13 and pfmdr1 ) were de- 
ected; b) measurements of lumefantrine blood levels at day 7 af- 
er treatment to rule out malabsorption ( Bell et al, 2009 ) were not
erformed. Nevertheless, both patients received treatment (with a 
eal) as hospital inpatients and signs of malabsorption were not 
etected. Artemisinin derivatives are rapidly metabolized (half-life 
1.5h) and cleared from circulation ( Hall et al, 2013 ), resulting in 
nly a single full parasite life cycle being exposed to the drug, un- 
er conditions of a 3-day regimen. Since lumefantrine half-life is 
-10 days ( Bretscher et al, 2020 ), is the current practice of 3 days
f treatment sufficient to guarantee clearance of parasites? 
onclusions 
These observations reveal a need for close monitoring of signs 
f unsatisfactory antimalarial efficacy among AL treated patients 
nd the possible involvement of other loci in the parasite’s re- 153 ponse to AL, especially because conditions for malaria reintroduc- 
ion in Portugal are still present in the country. 
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